UNSPSC 51434918: Candesartan/hydrochlorothiazide

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.

UNSPSC 51434918 Candesartan/hydrochlorothiazide is a Commodity code that names a single antihypertensive agent, but state and local governments procure under this code as part of broader pharmaceutical purchasing for emergency medical services, clinical settings, and health benefit programs. Recent solicitations show state and local buyers acquiring medications across multiple therapeutic classes—not limited to this specific drug—through competitive bidding and cooperative purchasing arrangements. The City of Tampa's Tampa Fire Rescue acquired advanced life support medications including labetalol, epinephrine, adenosine, and diltiazem through sealed bid; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) solicited generic multi-source pharmaceuticals and OTC products for distribution across participating state and local facilities; and the Texas Health and Human Services Commission conducted market research on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. Issuing bodies include municipal fire departments, state health agencies, and regional cooperative purchasing consortia. The code does not reflect a narrow single-drug market—instead, it sits within a larger purchasing taxonomy where state and local buyers tag pharmaceutical procurements at the commodity level while typically seeking portfolios of agents within and across therapeutic categories.

Recent activity centers in Florida, Minnesota, and Texas, with geographic reach extending to participating cooperative purchasing members across multiple states. The City of Tampa's sealed bid for Tampa Fire Rescue (26P00188, due April 8, 2026, estimated value $40,000) required four specific medication line items with nine-month minimum expiration and one-year warranty, with a 5 percent bid discount for Small Local Business Enterprise participation. The Minnesota MMCAP RFP (S1070000015802, due March 26, 2026) established contracts for generic multi-source pharmaceuticals and OTC products effective July 1, 2026, through three authorized wholesalers with pricing weighted 75 percent on competitiveness and performance penalties ranging from $200 to $1,500 per violation. The Texas HHS Commission's RFI (HHS0017013, posted April 3, 2026) gathered market intelligence on direct-to-manufacturer prescription delivery outside traditional PBM and GPO channels, signaling potential future formal solicitations. None of these opportunities was limited to candesartan/hydrochlorothiazide specifically; the code appears to classify individual pharmaceuticals within a much broader state and local procurement ecology.